FDA Issues New Final Guidance to Strengthen Potency Standards for Cell and Gene Therapies

The U.S. Food and Drug Administration has released new final guidance aimed at improving how manufacturers assess and maintain the potency of cellular and gene therapies. This regulatory update seeks to ensure that innovative treatments, including advanced cancer therapies like CAR-T, remain effective throughout their entire product lifecycle. The guidance replaces standards that had been in place for approximately 15 years. By modernizing these requirements, the agency intends to provide clearer expectations for developers working in the rapidly evolving field of biological medicine. Potency is defined under federal regulations as the specific ability or capacity of a product to produce its intended therapeutic effect. Because these therapies are often complex and derived from living cells, maintaining consistent potency is a fundamental quality attribute. The new framework encourages companies to integrate potency assurance from the earliest stages of investigational new drug development. This approach continues through the biologics license application process and extends into post-marketing quality monitoring. Karim Mikhail, the Director of the FDA’s Center for Biologics Evaluation and Research, highlighted the importance of reliable product quality for patient safety. He noted that the agency is committed to supporting the development of high-quality biological products through clear, science-based standards. The guidance suggests that developers should not rely exclusively on testing the final product to prove its effectiveness. Instead, the FDA recommends a risk-based approach that accounts for the unique biological properties of each therapy. This shift acknowledges that developers may not have fully characterized every biological property during early-phase clinical investigations. As a result, the agency expects potency assurance strategies to evolve as more data becomes available during the clinical development process. This flexibility is intended to facilitate innovation while maintaining rigorous safety and efficacy benchmarks. The updated guidance is expected to influence how pharmaceutical companies design their manufacturing and testing protocols for years to come. By emphasizing transparency and predictability, the FDA aims to streamline the path for new therapies to reach patients who need them. Industry experts suggest that this move will help standardize quality control across the sector. The new rules are effective immediately for all current and future applicants seeking regulatory approval for cell and gene-based products.